Premium
P3‐038: Development of conformational FRET‐ based detection of amyloid beta oligomers in clinical samples
Author(s) -
Soukharev Serguei
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.1215
Subject(s) - förster resonance energy transfer , fluorophore , peptide , chemistry , oligomer , biophysics , amyloid (mycology) , circular dichroism , fluorescence , protein secondary structure , amyloid beta , biochemistry , biology , inorganic chemistry , physics , organic chemistry , quantum mechanics
Background: To compare CSF levels of beta-amyloid 1-42 (Abeta(1-42)), total tau (Tau) and tau phosphorylated at threonine 181 (pTau-181) between AD patients with different onset of the disease and controls. Methods: 76 AD patients (mean age and SD, 74.296 5.41) with classic onset of the disease ([[Unsupported Character ?]]65 years), 35AD patients (mean age and SD, 54.666 5.38) with early onset (<65 years) and 35 control subjects (mean age and SD, 70.15 6 11.10) underwent lumbar puncture. The Innotest, ELISA sandwich test (Innogenetics-Belgium) was used for measuring the levles of Tau, pTau-181 and Abeta(1-42). Results: All three biomarkers showed main effects of diagnosis (p< 0.001). When series of ANCOVAs, with age as covariate were performed, the significant difference still exist. There were no difference according to age of onset among AD patients with classic and early onset of the disease (Abeta(1-42) 449 6 209 versus 460 6 206 pg/ml; Tau 6976 603 versus 5496 298 pg/ml; pTau-181; 1306 88 versus 1316 73 pg/ml). Conclusions: The obtained results suggest that these biomarkers may be supportive in the diagnosis of AD in routine clinical paractice considering the approaching new target therapeutics.